Vincent Montoya, Andrea D. Olmstead, Naveed Z. Janjua, Patrick Tang, Jason Grebely, Darrel Cook, P. Richard Harrigan, Mel Krajden – 2 February 2015 – The ability to classify acute versus chronic hepatitis C virus (HCV) infections at the time of diagnosis is desirable to improve the quality of surveillance information. The aim of this study was to differentiate acute from chronic HCV infections utilizing deep sequencing.

Qing Pang, Xin Sen Xu, Jing Yao Zhang, Kai Qu, Wei Chen, Chang Liu – 2 February 2015

Massimo Iavarone, Giuseppe Cabibbo, Marco Biolato, Cristina Della Corte, Marcello Maida, Marco Barbara, Michele Basso, Sara Vavassori, Antonio Craxì, Antonio Grieco, Carlo Cammà, Massimo Colombo – 2 February 2015 – Treatment with sorafenib of patients with advanced hepatocellular carcinoma is challenged by anticipated discontinuation due to tumor progression, liver decompensation, or adverse effects.

Alessandro Vitale, Michael Volk, Umberto Cillo – 31 January 2015

Scott W. Biggins – 31 January 2015

Erkan Parlak, Fahrettin Küçükay, Aydın Şeref Köksal, Ahmet Tarık Eminler, Mustafa İhsan Uslan, Sezai Yılmaz – 31 January 2015

Yael Asman, Amy R. Evenson, Einat Even‐Sapir, Oren Shibolet – 31 January 2015 – Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third most common cause of cancer‐related death worldwide. Orthotopic liver transplantation (OLT) and resection are curative treatment options for well‐selected patients with HCC, whereas loco‐ablative therapy has been shown to prolong survival.

Naoko Kamo, Toshimi Kaido, Ahmed Hammad, Kohei Ogawa, Yasuhiro Fujimoto, Tadahiro Uemura, Akira Mori, Etsuro Hatano, Hideaki Okajima, Shinji Uemoto – 31 January 2015 – Elderly donor grafts for liver transplantation (LT) are recognized to be marginal grafts. The present study investigated the impact of using elderly donors for LT. Between June 1990 and August 2012, 1631 patients received LT at Kyoto University Hospital. Out of 1631 patients, 1597 patients received living donor liver transplantation (LDLT), whereas the other 34 patients underwent deceased donor liver transplantation (DDLT).

Hyeon Seok Hwang, Cheol Whee Park, Myeong Jun Song – 30 January 2015 – Tenofovir disoproxil fumarate (TDF) is widely used as an effective first‐line therapy for chronic hepatitis B (CHB) infection. While TDF demonstrates successful viral suppression, it has been linked to the development of renal proximal tubular (PT) dysfunction, leading to Fanconi syndrome. However, Fanconi syndrome has been rarely reported in CHB‐monoinfected patients, and there were no reports of TDF‐associated nephrotic syndrome.

Hyeon Seok Hwang, Cheol Whee Park, Myeong Jun Song – 30 January 2015 – Tenofovir disoproxil fumarate (TDF) is widely used as an effective first‐line therapy for chronic hepatitis B (CHB) infection. While TDF demonstrates successful viral suppression, it has been linked to the development of renal proximal tubular (PT) dysfunction, leading to Fanconi syndrome. However, Fanconi syndrome has been rarely reported in CHB‐monoinfected patients, and there were no reports of TDF‐associated nephrotic syndrome.